DOCUMENTARY RESEARCH · UNITED STATES
Take a closer look at the questions that matter when reading a provider’s offer.
SCIENTIFIC ARTICLE
Semaglutide reduced a major cardiovascular composite in people with established cardiovascular disease and no diabetes. Understanding the endpoint, absolute difference, and treatment discontinuations is essential to interpreting that benefit.
SCIENTIFIC ARTICLE
Semaglutide reduced a combined kidney and cardiovascular outcome in people with type 2 diabetes and chronic kidney disease. Understanding who entered FLOW—and what counted as an event—is essential to applying the result responsibly.
SCIENTIFIC ARTICLE
Randomized tirzepatide withdrawal separates maintaining a treatment effect from finishing a course. Reading its two baselines—and newer maintenance-dose research—shows what the evidence can and cannot tell patients changing care.
SCIENTIFIC ARTICLE
A year after semaglutide and structured lifestyle support ended, participants regained about two-thirds of their earlier weight loss on average. The study supports planning for continuity—not predicting everyone’s future.
SCIENTIFIC ARTICLE
Tirzepatide produced greater average weight and waist reductions than semaglutide over 72 weeks. Understanding the trial’s design matters just as much as understanding the difference.
SCIENTIFIC ARTICLE
Two randomized trials found substantial reductions in breathing interruptions with tirzepatide. Understanding the results requires separating hourly event counts, PAP history, residual disease, and ongoing clinical responsibility.
SCIENTIFIC ARTICLE
The 529-person trial connected semaglutide with better heart-failure symptom scores, greater weight loss, and improved walking performance over 52 weeks. Understanding those endpoints helps separate meaningful clinical evidence from claims about survival, products, or care programs.
SCIENTIFIC ARTICLE
Tirzepatide reduced a combined cardiovascular-death or worsening-heart-failure endpoint in people with obesity and preserved ejection fraction. Understanding which events changed—and which remain uncertain—is essential to reading the result correctly.
SCIENTIFIC ARTICLE
Among participants with obesity and prediabetes, tirzepatide substantially reduced progression to type 2 diabetes over 176 weeks. The short period after treatment ended helps define—and limit—what that finding means for lasting protection.
SCIENTIFIC ARTICLE
The SURMOUNT-1 DXA substudy found that most lost weight was fat, but lean tissue also declined. Understanding the denominators—and what the scans did not measure—is essential to interpreting the result.
READING GUIDE
Real examples from six telehealth services show why clinical approval, insurance authorization, pharmacy fulfillment and ongoing care are separate steps—not one guaranteed transaction.
READING GUIDE
Canceling a subscription, canceling a pharmacy order and making a clinical treatment decision are different tasks. Six providers’ public documents show why each needs its own confirmation.
READING GUIDE
The brand on the website may coordinate your care without employing your prescriber. Here is how six GLP-1 platforms describe their medical groups, clinical professionals, pharmacies and support teams—and where their documentation leaves questions.
READING GUIDE
FDA recommends not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration. Here is how to contact the right people, document the problem and separate shipping promises from product-specific answers.
READING GUIDE
Insurance can change more than the medication bill: it may alter appointment requirements, prescription routing and refill timing. Six provider examples show where responsibilities shift—and why individual coverage needs separate confirmation.
READING GUIDE
A two-day eligibility decision, a prescription shipped within a week and a package arriving after dispatch describe different steps. Here is how to read six providers’ documented timelines without turning estimates into arrival guarantees.
READING GUIDE
Build a medication, allergy and health-history summary, then clarify who will evaluate you, prescribe, dispense and provide follow-up. Preparation supports a clinical conversation—not a do-it-yourself eligibility decision.
READING GUIDE
A practical guide to understanding who answers treatment questions, what ongoing support includes and where online messaging stops short—using six providers’ public documentation.
READING GUIDE
A care-delivery guide to distinguishing FDA-approved products from compounded preparations, identifying individual medical need and checking who is responsible at each handoff.
READING GUIDE
Medical messaging, customer service, scheduled visits and prescription renewals are different services. Here is how six telehealth programs document those responsibilities—and what to clarify before enrolling.
READING GUIDE
A prescription does not identify every organization responsible for your medicine. Six providers’ public documents show why pharmacy choice, formulation, payment and delivery need separate confirmation.
READING GUIDE
STEP 1 and SURMOUNT-1 can inform a conversation about benefits and risks. They cannot establish a telehealth provider’s results, validate a compounded formulation, or explain who will handle your follow-up.